Statement: Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis.
Primary_evidence: Adverse Events 1:   Total: 3/73 (4.11%)   Chest Pain - cardiac  1/73 (1.37%)   Myocarditis  1/73 (1.37%)   Pericarditis  1/73 (1.37%)   Ventricular tachycardia  1/73 (1.37%)   Skin infection  0/73 (0.00%)   Dermatitis radiation  0/73 (0.00%)   Dyspnea  1/73 (1.37%) Adverse Events 2:   Total: 3/70 (4.29%)   Chest Pain - cardiac  0/70 (0.00%)   Myocarditis  0/70 (0.00%)   Pericarditis  0/70 (0.00%)   Ventricular tachycardia  0/70 (0.00%)   Skin infection  2/70 (2.86%)   Dermatitis radiation  1/70 (1.43%)   Dyspnea  0/70 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 4/43 (9.30%)   Hemoglobin  [1]1/43 (2.33%)   Hemorrhage/Bleeding  [2]1/43 (2.33%)   Neutrophils/granulocytes (ANC/AGC)  [3]1/43 (2.33%)   Platelets  [4]1/43 (2.33%)   Anorexia  [5]1/43 (2.33%)   Sodium, serum-low (hyponatremia)  [1]1/43 (2.33%)   Thrombosis/thrombus/embolism  [6]2/43 (4.65%)